Impact of Immunotherapy after Resection of Pancreatic Cancer Thuy B. Tran, MD, Vijay K. Maker, MD, FACS, Ajay V. Maker, MD, FACS Journal of the American College of Surgeons Volume 229, Issue 1, Pages 19-27.e1 (July 2019) DOI: 10.1016/j.jamcollsurg.2019.01.016 Copyright © 2019 American College of Surgeons Terms and Conditions
Figure 1 Kaplan-Meier survival curve stratified by type of adjuvant therapy: (A) unmatched cohort and (B) matched cohort. CTx, chemotherapy; IT, immunotherapy. Journal of the American College of Surgeons 2019 229, 19-27.e1DOI: (10.1016/j.jamcollsurg.2019.01.016) Copyright © 2019 American College of Surgeons Terms and Conditions
Figure 2 Subgroup analysis on overall survival comparing chemotherapy (CTx) only vs CTx+immunotherapy (IT) in the propensity-matched cohort factors with high-risk factors: (A) R1 margin status, (B) positive lymph node, and (C) poorly differentiated disease. Journal of the American College of Surgeons 2019 229, 19-27.e1DOI: (10.1016/j.jamcollsurg.2019.01.016) Copyright © 2019 American College of Surgeons Terms and Conditions